Literature DB >> 21144805

Persistence of unrepaired DNA double strand breaks caused by inhibition of ATM does not lead to radio-sensitisation in the absence of NF-κB activation.

Stephany J Veuger1, Barbara W Durkacz.   

Abstract

The stress-inducible transcription complex NF-κB induces the transcription of genes that regulate proliferation and apoptosis. Constitutively activated NF-κB is common in breast cancers, and contributes to malignant progression and therapeutic resistance. Ataxia telangiectasia mutated (ATM) is a key regulator of the cellular response to DNA double strand breaks (DSBs), and recent reports have demonstrated that ATM is required for the activation of NF-κB following DNA damage. We investigated the role of ATM in the NF-κB signalling cascade induced by ionising radiation (IR) in breast cancer cell lines using KU55933, a novel and specific inhibitor of ATM. KU55933 suppressed IR-induced IκBα degradation, p50/p65 nuclear translocation and binding to kB consensus sequences. KU55933 also suppressed transcription of an NF-κB dependent reporter gene and inhibited IR-induced DSB repair as assessed by the neutral Comet assay. KU55933 sensitised cells to IR, with a concurrent increase in caspase 3 activity. Importantly, KU55933 sensitised IKKβ(+/+) and p65(+/+), but not IKKβ(-/-) or p65(-/-), mouse embryonic fibroblasts to IR, despite the equivalent inhibitory effects of KU55933 on DSB repair in both the proficient and the deficient cell lines. P65 siRNA had no effect on DSB repair in either breast cancer cell line. When combined with KU55933, DSB repair was inhibited to the same extent as KU55933 alone in both breast cancer cell lines. P65 siRNA alone sensitised both cell lines to IR. A combination of p65 siRNA and KU55933 resulted in no further sensitisation compared to either one alone. Taken together these data support the hypothesis that KU55933-mediated radio-sensitisation is solely a consequence of its inhibition of NF-κB activation. We conclude that radiotherapy deploying ATM inhibitors may be particularly advantageous in tumours where NF-κB is constitutively activated.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21144805     DOI: 10.1016/j.dnarep.2010.11.005

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  7 in total

1.  NF-κB in Aging and Disease.

Authors:  Jeremy S Tilstra; Cheryl L Clauson; Laura J Niedernhofer; Paul D Robbins
Journal:  Aging Dis       Date:  2011-12-02       Impact factor: 6.745

2.  Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60).

Authors:  Jiřina Vávrová; Lenka Zárybnická; Emilie Lukášová; Martina Řezáčová; Eva Novotná; Zuzana Sinkorová; Aleš Tichý; Jaroslav Pejchal; Kamila Durišová
Journal:  Radiat Environ Biophys       Date:  2013-08-11       Impact factor: 1.925

3.  The Breast Cancer Tumor Suppressor TRIM29 Is Expressed via ATM-dependent Signaling in Response to Hypoxia.

Authors:  Muzaffer Dükel; W Scott Streitfeld; Tsz Ching Chloe Tang; Lindsey R F Backman; Lingbao Ai; W Stratford May; Kevin D Brown
Journal:  J Biol Chem       Date:  2016-08-17       Impact factor: 5.157

4.  Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor κ light chain enhancer of activated B cells (NFκB) signaling controls basal and DNA damage-induced transglutaminase 2 expression.

Authors:  Lingbao Ai; Ryan R Skehan; John Saydi; Tong Lin; Kevin D Brown
Journal:  J Biol Chem       Date:  2012-04-04       Impact factor: 5.157

Review 5.  MicroRNA and signal transduction pathways in tumor radiation response.

Authors:  Luqing Zhao; Xiongbin Lu; Ya Cao
Journal:  Cell Signal       Date:  2013-04-17       Impact factor: 4.315

Review 6.  Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity.

Authors:  Luqing Zhao; Ann M Bode; Ya Cao; Zigang Dong
Journal:  Carcinogenesis       Date:  2012-07-12       Impact factor: 4.944

7.  Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of BRCA2 mutation carriers.

Authors:  Mihriban Karaayvaz-Yildirim; Rebecca E Silberman; Adam Langenbucher; Srinivas Vinod Saladi; Kenneth N Ross; Elena Zarcaro; Andrea Desmond; Murat Yildirim; Varunika Vivekanandan; Hiranmayi Ravichandran; Ravindra Mylavagnanam; Michelle C Specht; Sridhar Ramaswamy; Michael Lawrence; Angelika Amon; Leif W Ellisen
Journal:  Sci Adv       Date:  2020-01-29       Impact factor: 14.136

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.